Related Experiment Video
Updated: Jul 3, 2026
06:55
Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Summary
The Secretary can now collect Medicare Part D claims data for vital research and public health functions. This allows for better oversight, public health protection, and evaluation of the Medicare Modernization Act (MMA).
Area of Science:
- Health Policy
- Public Health
- Health Services Research
Background:
- Medicare Part D claims data are currently collected for payment purposes.
- Existing publicly available data are insufficient for comprehensive oversight and research.
- The Department of Health and Human Services (HHS) has obligations for Medicare program oversight and public health protection.
Purpose of the Study:
- To enable the Secretary to collect existing Part D claims data for broader research, analysis, reporting, and public health functions.
- To improve the ability to identify, evaluate, and measure the effects of the Medicare Modernization Act (MMA).
- To fulfill HHS's obligations in overseeing the Medicare program and protecting public health.
Main Methods:
- Leveraging claims data already collected for Medicare Part D payment purposes.
- Utilizing these data for research, analysis, reporting, and public health initiatives.
- Applying data analysis to assess the impact of the Medicare Modernization Act (MMA).
Main Results:
- The Secretary is authorized to collect and utilize Part D claims data for specified purposes.
- Enhanced data collection supports critical research and public health functions.
- Improved capacity to evaluate the effectiveness of the Medicare Modernization Act (MMA).
Conclusions:
- This rule facilitates the use of valuable claims data for essential governmental functions.
- The expanded use of data will strengthen Medicare program oversight and public health initiatives.
- The initiative supports evidence-based policy-making and program evaluation, particularly concerning the MMA.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:02Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...